• Non ci sono risultati.

Assunta Saide

N/A
N/A
Protected

Academic year: 2022

Condividi "Assunta Saide"

Copied!
2
0
0

Testo completo

(1)

Page 1 of 2 Assunta Saide - Curriculum vitae

Assunta Saide

Born in Naples (Italy) on 04/11/1985 Tel.: +39 081 5833221

Fax: +39 081 7641355 e-mail: [email protected] Skype: susy.saide

Current Position: Post-doc Fellow Supervisor: Dott.ssa Adrianna Ianora Appointed on project: ADVISE

Affiliation:

Section Marine Biotechnology, Stazione Zoologica Anton Dohrn, Napoli (Italy)

Education/Training/Experience

Institute and Location Degree / Function

Year Field of Study University of Naples Federico

II, Naples Italy.

Bachelor Sc. 2005-2008 Biotechnology for health.

University of Naples Federico II, Naples Italy.

Master Sc. 2008-2010 Medical Biotechnology.

University of Campania Luigi Vanvitelli and Telethon Institute of Genetics and Medicine.

Naples, Italy

Ph.D. 2010-2013 Medical Genetics.

Reithera s.r.l

(Biopharmaceutical company).

Naples, Italy

Biotechnologist 2014-2015 Molecular and Cellular Biology

University of Naples Federico II, Department of Pharmacy.

Naples, Italy.

Post doc 2016-2018 Biochemistry and Cellular Biology

CEINGE, Naples, Italy Cell culture facility

2018-2019 Cellular Biology and Biotechnology

(2)

Page 2 of 2 Assunta Saide - Curriculum vitae

supervisor and coordinator Stazione Zoological Anton

Dohrn. Naples, Italy. Research fellow 2019-now Marine Biotechnology

Publications

Author of 5 publications on ISI-journals

Journal Papers

Imperatore C., Scuotto M., Valadan M., Rivieccio E., Saide A., Russo A., Altucci C., Menna M., Ramunno A., Mayol L., Russo G., Varra M. (2019).

Photo control of cancer cel growth by benzodiazo N-substituted pyrrole derivatives. Journal of Photochemistry and Photobiology A:Chemistry 377: 109-118.

Russo A., Saide A., Smaldone S., Faraonio R., Russo G. (2017).

Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells.

Int. J Mol. 18 (3), 547.

Russo A., Saide A., Cagliani R., Cantile M., Botti G., Russo G. (2016).

rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFkB upon 5-FU treatment. Scientific reports 6, 38369.

Pagliara V., Saide A., Mitidieri E., d’Emmanuele di Villa Bianca R., Sorrentino R., Russo G., Russo A. (2016). 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lackin p53. Oncotarget 7: 50333-50348.

de Pablo-Latorre R, Saide A, Polishhuck EV, Nusco E, Fraldi A, Ballabio A. (2012). Impaired parkin- mediated mitochondrial targeting to autophagosomes differentially contributes to tissue pathology in lysosomal storage diseases. Human molecular genetics 21:1770-81.

Riferimenti

Documenti correlati

The effects in vitro of lignans on proliferation of human colon cancer cells lines (HT29 and HCT8) showed that lignans inhibit cellular proliferation and induce arrest of cell

Data reported herein indicate that under chronic treatment with 5-FU, i) colon cancer cells resistant to 5-FU plastically shift their metabolism towards OXPHOS; ii) revert

To further test, if the ability to induce senescence or apoptosis is also a determinant for lifespan length, β-galactosidase activity and AnnexinV(+) cells abundance were measured

As in the induction of apoptosis, we found that p53 was not important for upregulation of death receptors by CD437 in human prostate and head and neck cancer cells, because

Among them MSI status (microsatellite instability) has already been shown to in fluence survival and response to adjuvant infusional 5-FU in colon cancer patients ( Sargent et al.,

Prognostic value of proliferation, apoptosis, defective DNA mismatch repair and p53 overexpression in patients with resected Dukes B2 or C colon cancer: a north central

In particular, we examined the effects of AS601245 and clofibrate, alone or in association, on apoptosis, differentiation, and PPRE binding activity of PPAR α in CaCo-2 human colon

Semba et al (2002) produced similar tumor cell apoptosis and suppression of tumor growth utilizing the PI3K inhibitor, LY294002, in multiple human colon cancer cell lines in